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Background. Recurrent bacterial infections play a key role in the pathogenesis of bronchiectasis, but conventional microbiologic
methods may fail to identify pathogens in many cases. We characterized and compared the pulmonary bacterial communities
of cystic ﬁbrosis (CF) and non-CF bronchiectasis patients using a culture-independent molecular approach. Methods.B a c t e r i a l
16S rRNA gene libraries were constructed from lung tissue of 10 non-CF bronchiectasis and 21 CF patients, followed by DNA
sequencing of isolates from each library. Community characteristics were analyzed and compared between the two groups. Results.
A wide range of bacterial diversity was detected in both groups, with between 1 and 21 bacterial taxa found in each patient.
Pseudomonas was the most common genus in both groups, comprising 49% of sequences detected and dominating numerically in
13 patients. Although Pseudomonas appeared to be dominant more often in CF patients than in non-CF patients, analysis of entire
bacterial communities did not identify signiﬁcant diﬀerences between these two groups. Conclusions. Our data indicate signiﬁcant
diversity in the pulmonary bacterial community of both CF and non-CF bronchiectasis patients and suggest that this community
is similar in surgically resected lungs of CF and non-CF bronchiectasis patients.
1.Introduction
Bronchiectasis is a heterogenous condition characterized by
chronic infection/inﬂammation and irreversible abnormal
dilatation of the airways. Generally classiﬁed into cystic
ﬁbrosis (CF) and non-CF disease, bronchiectasis was asso-
ciated with a high mortality rate in the preantibiotic era [1].
While the outcome of bronchiectasis, both CF and non-CF,
has improved signiﬁcantly, non-CF bronchiectasis (hereafter
referred to simply as bronchiectasis) nevertheless remains a
signiﬁcant cause of respiratory morbidity that necessitates
surgical resection and even lung transplantation in some
patients.
While the cause of CF has been pinpointed to mutations
in a single gene, non-CF bronchiectasis may be associated
with a wide range of diﬀerent conditions including ciliary
dysmotility syndromes, immune deﬁciencies, and chronic
obstructive pulmonary disease (COPD) and, in many cases,
is idiopathic [2]. The common underlying pathogenic mech-
anism, however, appears to be recurrent airway infection and2 Pulmonary Medicine
inﬂammation resulting in scarring and permanent dilatation
of the airways.
Giventhecentralityofairwayinfectioninthepathogene-
sis of bronchiectasis, a number of studies have endeavored to
identify bacterial pathogens present in these patients, using
conventional microbiologic methods [3–11]. Such studies
have typically found the most common pathogens to be
nontypable Haemophilus inﬂuenzae and Pseudomonas aerug-
inosa, followed by a handful of others including Moraxella
catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus,
and coliforms. Nontuberculous mycobacteria have also been
reported with variable frequency. Such studies suggest that,
despite seemingly similar pathophysiologic mechanisms,
there may be diﬀerences in the bacterial species infecting
CF and non-CF bronchiectasis patients. For example, while
H. inﬂuenzae is the most common pathogen in adult non-
CF bronchiectasis (approximately 40% of cases), it is far less
prevalent in adult CF patients [1, 12]. On the other hand, P.
aeruginosa is far more commonly isolated among adult CF
patients than from bronchiectasis patients (approximately
80% versus 18%, resp.) [1, 12]. Further, the Burkholderia
cepaciacomplex,agroupoforganismsassociatedwithsignif-
icantly impaired outcome in CF patients, infects bronchiec-
tasispatientsquiteinfrequentlyincomparisontoCFpatients
[13]. These observations suggest that despite similar changes
in the disease morphology within the airways, other factors
and mechanisms may be at play in determining what
organisms are able to infect each group of patients.
These studies, however, almost certainly underestimate
thebacterialdiversityofthelungsinpatientswithbronchiec-
tasis, given that 30–40% of sputum samples may fail to grow
pathogenic bacteria in conventional culture, despite being of
good quality and purulent [2]. Such studies, therefore, may
underestimate the extent of diversity and variation within
the pulmonary bacterial ﬂora associated with bronchiectasis.
Application of the methods and strategies of an emerging
ﬁeld of study known as metagenomics may help address
these issues. Metagenomics is the study of communities
of organisms using genetic material taken directly from
theirnaturalenvironment[14].Metagenomics’powercomes
from its ability to assess community structure and dynamics
without needing ﬁrst to isolate and propagate organisms
in the laboratory. Free of the constraints and limitations
imposed by culture-based methods, it provides a semiquan-
titative assessment of community diversity. Communities
can be studied without any prior knowledge of their
composition and without the need for speciﬁc selective
conditions, by isolating and characterizing DNA directly
from the metagenome—that is, the combined genomes of
all species present in the specimen of interest—bypassing the
need for laboratory isolation and cultivation. The potential
p o w e ro fm e t a g e n o m i c st oi n v e s t i g a t eq u e s t i o n sr e l a t e d
to health and disease has been increasingly recognized
in recent years, as evidenced, for example, by the recent
launches of the International Human Microbiome Con-
sortium (http://www.human-microbiome.org/), the Human
Microbiome Project (HMP), and other similar initiatives
around the world [15, 16].
A growing number of studies using culture-independent
molecular strategies for detection of bacterial species have
demonstrated striking diversity of the pulmonary bacterial
community in CF patients [17–27]. However, few if any
similar studies have been done to characterize pulmonary
bacterial communities in bronchiectasis. We, therefore,
endeavoredtoproﬁlethediversityofthepulmonarybacterial
community in patients with bronchiectasis by sequencing
bacterial 16S rRNA gene libraries constructed using surgi-
callyexcisedlungtissuefrom10patientswithbronchiectasis;
we compared these communities to those seen in 21 patients
with CF.
2. Methods
2.1. Patients and Sample Collection. Protocols for speci-
men collection, storage, and use were approved by the
University Health Network (UHN) Research Ethics Board.
Under aseptic conditions, tissue specimens were collected
from patients with an established diagnosis of either CF
or non-CF bronchiectasis undergoing surgical resection
(pneumonectomy) or lung transplantation at the Toronto
General Hospital between 1998 and 2007. Peripheral lung
tissues were collected under sterile conditions intraopera-
tively, ﬂash frozen in liquid nitrogen, and stored at −80◦C.
Specimens from 10 patients with non-CF bronchiectasis and
21randomlyselectedCFpatientswereanalyzed(Table 1).All
specimen processing was performed blinded to patient data.
Clinical data were extracted from electronic patient records
at UHN.
2.2. DNA Extraction and 16S rRNA Gene Ampliﬁcation
and Sequencing. Genomic DNA was extracted using the
Direct PCR DNA Extraction System (Viagen Biotech, Los
Angeles, CA). PCR reactions and negative controls were
prepared in a separate room from where ampliﬁcations were
conducted. Ampliﬁcation of 16S rRNA was performed using
the 8F (5 -AGAGTTTGATCCTGGCTCAG) and 806R (5 -
GGACTACCAGGGTATCTAAT) PCR primers, as follows: 1
cycle (95◦C, 5min); 30 cycles (95◦C, 30sec; 55◦C, 30sec;
72◦C, 30sec); 1 cycle (72◦C, 8min). Amplicon libraries for
each specimen were constructed using the TA cloning kit
(Invitrogen,Carlsbad,CA)andplatedonLBmedia.Plasmids
from individual isolates were puriﬁed using the Pure Link
Quick Plasmid Miniprep kit (Invitrogen). DNA sequencing
was performed on an Applied Biosystems 3130XL sequencer
(Analytical Genetics Technology Centre, Toronto) on up to
48 isolates initially, followed by preliminary assessment of
diversityusingBLAST[28].Specimenscontainingmorethan
onetaxonweresubjectedtoadditionalsequencing.Chimeras
were identiﬁed by BLAST analysis of end sequences and
excluded from analysis.
2.3. Data Analysis. Sequences were analyzed using the Qiime
community analysis pipeline [29]. Sequences were clustered
into operational taxonomic units (OTUs) using a 97% iden-
titythreshold.Onesequencerepresentingthemostabundant
from each OTU was chosen for taxonomic classiﬁcationPulmonary Medicine 3
using the RDP classiﬁer [30]. Taxonomy classiﬁcations with
a support level greater than or equal to 0.7 were retained;
this resulted in not all sequences being classiﬁed to the most
resolved (i.e., genus) level. All whole bacterial community
comparisons included all sequences regardless of the level to
which their taxonomy was assigned; however, for the identi-
ﬁcation and analysis of numerically dominant taxa, we chose
onlythoseOTUsclassiﬁedtothegenuslevelsincethishasthe
most functional information. OTU taxonomy classiﬁcations
were used to construct the OTU table used in rarefaction
analysis, heatmap construction, and distance calculations.
Rarefaction analysis was performed in Qiime [29], using
100 replicate samplings of the sequences for subsequent
estimation of alpha diversity. Calculation of UniFrac metrics
[31] and principal components analyses were done in Qiime
[29]. Clustering for heatmap presentation was performed in
R[ 32].
3. Results
3.1. Bacterial Community Diversity of the Lungs in Patients
with Bronchiectasis and CF. In total, 955 16S rRNA gene
sequences were obtained from lung tissue specimens of
10 patients with bronchiectasis (mean 96 ± 29 (sd) per
patient) and 1387 16S rRNA gene sequences from lung
tissue specimens of 21 patients with CF (mean 66 ± 24 (sd)
sequences per patient). Etiologies underlying the diag-
noses of bronchiectasis included postinfectious (4 patients),
immune dysfunction (3 patients), chronic obstructive pul-
monary disease (1 patient), and idiopathic (2 patients). Tax-
onomic classiﬁcation identiﬁed 37 unique operational taxo-
nomicunits(OTUs)representing20generainbronchiectasis
patients and 51 unique OTUs representing 29 genera in
CF patients, with 16.7 ± 2.9 OTUs representing 9.1 ± 1.7
genera per patient in bronchiectasis and 11.5 ± 6.0O T U s
representing 6.8 ± 3.5 genera per patient in CF (range 1–21)
(Table 1). These OTUs represented 4 phyla, Proteobacteria
beingmostnumerousinbothgroups(Table 2),andincluded
many taxa not typically reported as constituents of the
respiratory tract microﬂora (Table 3).
Pseudomonaswasthemostprevalentgenusoverall,witha
total of 9 OTUs being detected in 30 of 31 patients, including
all 10 bronchiectasis patients, and accounting for 49%
of all sequences (Table 3). However, Pseudomonas was the
numerically predominant genus (i.e., the genus represented
by the largest number of 16S rRNA sequences) in only 13
patients, with various other taxa predominating in the other
18 patients. Pseudomonas was numerically predominant
more frequently in CF patients (11/21 patients) than in
bronchiectasis (2/10 patients), although this diﬀerence was
not statistically signiﬁcant (P = 0.18, 2-sided Fisher’s Exact
Test). Sequences from other genera known to colonize adult
CF patients were also detected, including Stenotrophomonas
and Staphylococcus in both patient groups. Haemophilus was
detected in only 2 patients with CF and 1 patient with
bronchiectasis. Interestingly, Burkholderia sequences were
detected at low levels in 4 patients with bronchiectasis.
We used rarefaction analysis to determine whether
the number of sequences we obtained from each patient
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Figure 1: Rarefaction curves estimating the eﬀect of sampling on
Chao1 diversity measurements. The sequence data were resampled
100 times in Qiime [29], and, for each sample, the Chao1 diversity
measurement was estimated. Red lines indicate bronchiectasis
patients, whereas blue lines indicate cystic ﬁbrosis (CF) patients.
was a suﬃcient sample of the sequence diversity present.
Rarefaction analysis works by repeated sampling of the data;
with each of these samples, the OTU diversity is calculated
and plotted to determine whether the observed diversity
increases with more sampling. If the sampling saturates
the diversity present, then the curve will plateau, whereas
if there is additional diversity yet to be discovered, the
curve will continue to rise. Considering the relatively low
number of sequences we sampled for each patient, most
of the rarefaction curves indicate suﬃcient sampling of the
diversity present (Figure 1). Although there are a few patient
curvesthatareundersampled(i.e.,thatcontinuetoincrease),
thesearenotrestrictedtobronchiectasisorCFpatientsalone,
indicating that any potential diﬀerences in bronchiectasis
versus CF community structure are unlikely to be due to
insuﬃcient sampling.
3.2. Comparison of Pulmonary Bacterial Communities in
Bronchiectasis and CF. We compared the bacterial commu-
nities between bronchiectasis and CF patients in three ways:
clustering of community proﬁles, clustering of community
distances, and principal components analysis. Community
proﬁles were clustered and are represented in the heatmap
shown in Figure 2. Although there is a small cluster of
bronchiectasis-derived communities (B188, B150, B366, and
B193), those not clustered together are interspersed with the
CF communities.
The heatmap clustering is informative for comparing
patientsbasedontheircommunityproﬁlesbutdoesnotcon-
sider sequence diﬀerences within or between OTUs. There-
fore, we also compared the sequence divergence in these
community proﬁles within a phylogenetic framework by
calculating the normalized weighted UniFrac distance [31]4 Pulmonary Medicine
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Burkholderia OTU46
Bacillus OTU23
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Acinetobacter OTU56
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Variovorax OTU27
Streptococcus OTU57
Bradyrhizobium OTU21
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Comamonas OTU10
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Ralstonia OTU22
Bacteria OTU41
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Flavobacterium OTU13
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Pedobacter OTU34
Delftia OTU18
Flavobacteriaceae OTU32
Figure 2: Heatmap showing clustering of bacterial communities and similarities in operational taxonomic unit (OTU) distribution among
patients. Sample numbers are listed horizontally along the bottom; “B” indicates bronchiectasis samples, and “CF” indicates CF samples.
OTUs and their taxonomic classiﬁcations are listed vertically on the right. Darker colors indicate higher abundance; lighter colors indicate
low abundance or absence of a particular OTU.
and using these distances to infer a UPGMA phylogenetic
tree (Figure 3). As is clear from the grouping of diﬀerent
patients in the tree, there exist no clear diﬀerences between
bacterial communities from bronchiectasis and CF patients.
In fact, when sequence divergence is taken into account, the
small cluster of bronchiectasis patients noted in Figure 2 is
no longer present (Figure 3).
Finally, we used principal components analysis (PCA) to
identifywhetherdiﬀerencesexistbetweenbronchiectasisand
CF communities. PCA is useful for removing correlations
in the data that may obscure the detection of diﬀerences
that exist due to a diagnosis of bronchiectasis versus CF
(e.g., age of patient). The results from PCA agree with the
results from the other two methods described above, namely,
that signiﬁcant diﬀerences in bacterial community structure
could not be found when comparing bronchiectasis to CF
patients (Figure 4).
4. Discussion
Bacterial infection is a major cause of morbidity in indi-
viduals with CF and non-CF bronchiectasis. ManagementPulmonary Medicine 5
Table 1: Sequences and OTUs for each patient.
Patient Source∗
Number of
rRNA
sequences
Number of OTUs
(number of
Pseudomonas OTUs)
Number
of genera
A141 CF 39 6 (1) 5
A89 B 81 21 (3) 12
8C F 5 4 1 7 ( 3 ) + 8
21 CF 38 11 (2)+ 6
33 CF 81 14 (4)+ 8
56 B 101 21 (3) 11
74 CF 79 20 (3) 13
88 CF 59 8 (1)+ 4
127 CF 86 14 (1)+ 8
131 CF 89 14 (1)+ 11
141 B 98 17 (4) 9
142 CF 87 10 (2)+ 5
150 B 90 13 (2) 7
153 CF 81 15 (3) 7
155 CF 28 1 (1)+ 1
167 CF 43 1 (1)+ 1
179 CF 63 14 (3) 9
181 CF 85 15 (3)+ 8
188 B 86 15 (4) 8
193 B 77 16 (2)+ 10
311 CF 18 1 (1)+ 1
312 CF 27 2 (0) 2
360 B 86 13 (2) 7
366 B 77 18 (2) 10
375 B 84 15 (3)+ 8
380 CF 91 15 (3) 8
381 CF 94 19 (3) 11
386 CF 70 16 (2) 11
391 CF 79 14 (3) 7
398 CF 76 13 (2) 8
29960 B 175 18 (4) 9
∗CF denotes cystic ﬁbrosis patients; B denotes bronchiectasis.
rRNA: ribosomal ribonucleic acid; OTU: operational taxonomic unit.
+Pseudomonas is the numerically predominant taxon.
Table 2: Phyla detected in lungs.
Phylum % sequences in CF
patients
% sequences in bronchiectasis
patients
Proteobacteria 57.3 64.6
Bacteroidetes 37.6 30.2
Actinobacteria 3.5 0.1
Firmicutes 1.6 5.1
of bacterial infections historically has been based primarily
on culture-based isolation of a limited number of species
considered pathogenic, but there is growing appreciation
of the polymicrobial nature of pulmonary infections par-
ticularly in the setting of chronic illnesses such as CF,
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Figure 3: Unweighted pair group method with arithmetic mean
(UPGMA) tree inferred using UniFrac distances. Red and blue
names indicate bronchiectasis and CF, respectively.
and increasing evidence indicates that interactions between
species may alter virulence properties or antibiotic suscepti-
bilityofindividualspecies[33].Betterunderstandingofsuch
interactions and their potential clinical impacts requires, as a
ﬁrststep,morecompletecharacterizationofthecomposition
of the microbial community of the lungs. We describe
here the application of culture-independent metagenomic-
based strategies to the study of the bacterial communities
of the lung. While a number of studies have applied similar
strategies to the study of respiratory microbiota in CF
patients [17–27], this study is, to our knowledge, the ﬁrst
reporting culture-independent sequence-based proﬁling of
bacterial species directly from lung tissue of patients with
non-CF bronchiectasis. Our data demonstrate signiﬁcant
diversity in the pulmonary bacterial communities of both
CF and bronchiectasis patients but did not detect signiﬁcant
diﬀerences in overall community composition between these
two groups of patients.
Proteobacteria predominated in both CF and non-CF
groups (Tables 2 and 3), with Pseudomonas being the
most prevalent genus overall. Pseudomonas was numerically
predominant in 2 of 10 patients with bronchiectasis, which
appears to be in keeping with previously reported rates of
isolation of P. aeruginosa from bronchiectasis patients in
the neighborhood of 18% [4]. Interestingly, however, while
Pseudomonas was numerically predominant in 2 bronchiec-
tasis patients, it was identiﬁed as a minor constituent of
the bacterial community in the remaining 8 bronchiectasis
patients. On the other hand, whereas H. inﬂuenzae is
typically cultured from approximately 40% of bronchiectasis6 Pulmonary Medicine
Table 3: Taxonomic classiﬁcation of all sequences.
Taxonomy Level of resolution Phylum Total sequences
Pseudomonas OTU14 Genus Proteobacteria 490
Delftia OTU18 Genus Proteobacteria 260
Flavobacteriaceae OTU32 Family Bacteroidetes 227
Delftia OTU37 Genus Proteobacteria 207
Flavobacteriaceae OTU26 Family Bacteroidetes 148
Flavobacteriaceae OTU61 Family Bacteroidetes 118
Pseudomonas OTU42 Genus Proteobacteria 110
Rhizobiaceae OTU1 Family Proteobacteria 102
Lysobacter OTU15 Genus Proteobacteria 98
Burkholderia OTU24 Genus Proteobacteria 72
Pedobacter OTU34 Genus Bacteroidetes 70
Brevibacillus OTU62 Genus Firmicutes 66
Azospirillum OTU49 Genus Proteobacteria 63
Rhizobium OTU53 Genus Proteobacteria 45
Pseudomonas OTU43 Genus Proteobacteria 42
Sphingomonas OTU17 Genus Proteobacteria 36
Staphylococcus OTU47 Genus Firmicutes 25
Pseudomonas OTU30 Genus Proteobacteria 23
Flavobacterium OTU13 Genus Bacteroidetes 20
Phyllobacterium OTU11 Genus Proteobacteria 14
Brevundimonas OTU58 Genus Proteobacteria 10
Massilia OTU64 Genus Proteobacteria 10
Paenibacillaceae OTU35 Family Firmicutes 9
Delftia OTU63 Genus Proteobacteria 7
Haemophilus OTU44 Genus Proteobacteria 6
Pseudomonas OTU39 Genus Proteobacteria 6
Delftia OTU8 Genus Proteobacteria 4
Flavobacterium OTU4 Genus Bacteroidetes 4
Pseudomonas OTU40 Genus Proteobacteria 4
Flavobacterium OTU52 Genus Bacteroidetes 3
Naxibacter OTU50 Genus Proteobacteria 3
Stenotrophomonas OTU12 Genus Proteobacteria 3
Brevundimonas OTU38 Genus Proteobacteria 2
Methylobacterium OTU19 Genus Proteobacteria 2
Pseudomonas OTU60 Genus Proteobacteria 2
Rhizobiales OTU16 Order Proteobacteria 2
Achromobacter OTU0 Genus Proteobacteria 1
Acidovorax OTU59 Genus Proteobacteria 1
Acinetobacter OTU5 Genus Proteobacteria 1
Acinetobacter OTU56 Genus Proteobacteria 1
Acinetobacter OTU7 Genus Proteobacteria 1
Anaeromyxobacter OTU20 Genus Proteobacteria 1
Bacillaceae OTU54 Family Firmicutes 1
Bacillus OTU23 Genus Firmicutes 1
Bacteria OTU41 Domain Bacteria 1
Bradyrhizobium OTU21 Genus Proteobacteria 1
Burkholderia OTU46 Genus Proteobacteria 1
Comamonas OTU10 Genus Proteobacteria 1
Flavobacteriaceae OTU55 Family Bacteroidetes 1
Hydrogenophaga OTU31 Genus Proteobacteria 1Pulmonary Medicine 7
Table 3: Continued.
Taxonomy Level of resolution Phylum Total sequences
Hyphomicrobium OTU33 Genus Proteobacteria 1
Massilia OTU28 Genus Proteobacteria 1
Methylophilus OTU2 Genus Proteobacteria 1
Mycobacterium OTU25 Genus Actinobacteria 1
Mycobacterium OTU29 Genus Actinobacteria 1
Oxalobacteraceae OTU48 Family Proteobacteria 1
Paenibacillaceae OTU3 Family Firmicutes 1
Pedobacter OTU51 Genus Bacteroidetes 1
Pseudomonas OTU36 Genus Proteobacteria 1
Pseudomonas OTU6 Genus Proteobacteria 1
Ralstonia OTU22 Genus Proteobacteria 1
Rhizobiales OTU9 Order Proteobacteria 1
Staphylococcus OTU45 Genus Firmicutes 1
Streptococcus OTU57 Genus Firmicutes 1
Variovorax OTU27 Genus Proteobacteria 1
OUT: operational taxonomic unit.
Non-CF
CF
−0.15 −0.1 −0.05 0 0.05 0.1 0.15 0.2 0.25
−0.15
−0.1
−0.05
0
0.05
0.1
0.15
0.2
P1-percent variation explained 47.7%
P
2
-
p
e
r
c
e
n
t
 
v
a
r
i
a
t
i
o
n
 
e
x
p
l
a
i
n
e
d
 
1
3
.
8
3
%
PCA: P1 versus P2
Figure 4: Principal components analysis (PCA) of bronchiectasis
(red) and CF patients (blue).
patients, it was detected in only 1 of 10 bronchiectasis
patients in this study. The reasons for these discrepancies
between our culture-independent data and previous culture-
based studies may be several-fold. Given that the present
study examined tissue samples from resected lung specimens
including many from patients undergoing lung transplanta-
tion, the bacterial community proﬁles generated here most
likely represent those present in end-stage lung disease,
and, together with the relatively small number of specimens
proﬁled here, therefore may not be completely representative
of the microﬂora in earlier stages of disease process. Further,
this study examined lung tissue samples, whereas previous
studies of bacterial species in bronchiectasis were based
largely on cultures of sputum samples. Because H. inﬂuenzae
frequently colonizes the upper respiratory tract, it may be
the case that previous sputum-based studies have overes-
timated the prevalence of H. inﬂuenzae in the lung itself.
Finally, the high frequency of Pseudomonas d e t e c t i o ni no u r
bronchiectasis data set compared to culture-based studies
couldpossiblybeduetoinhibitionofgrowthofPseudomonas
in culture by interspecies interactions with other, more
prevalent species present within sputum samples. Such
inhibition could possibly account for at least part of the
large proportion of sputum samples from bronchiectasis
patients in which no pathogens are detected by conventional
culture methods [2]. Similar factors could also account for
our detection of Burkholderia in 4 of 10 bronchiectasis
patients, whereas a previous culture-based study failed to
isolate any Burkholderia from sputum samples of patients
with bronchiectasis [13].
Comparison of pulmonary bacterial community proﬁles
from bronchiectasis patients with those obtained from CF
patients using three diﬀerent methods found no signiﬁcant
diﬀerences in community structure between the two groups.
At this point, it is uncertain whether this is simply a function
of the fact that the specimens analyzed in this study were
derived from end-stage lungs (both CF and non-CF) and
whether the pulmonary bacterial communities of CF and
bronchiectasis patients at earlier stages may demonstrate
more signiﬁcant diﬀerences. Longitudinal studies proﬁling
respiratory samples from bronchiectasis patients in compar-
ison with CF patients over time are needed to shed light on
this question.
In summary, our data indicate signiﬁcant diversity in
the bacterial community of the lungs in both CF and
non-CF bronchiectasis patients but did not detect sig-
niﬁcant diﬀerences in the bacterial community structure8 Pulmonary Medicine
between these two groups. The application of culture-
independent methods, such as those described here, in
concert with conventional culture-based studies should help
signiﬁcantly advance understanding of the microbiology of
the bronchiectatic airway.
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